MedTrace Logo

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-01-27

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is:

Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA

Researchers will compare the effects with placebo group after 6 months of treatment

Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Conditions

  • Acute Coronary Syndromes
  • Coronary Arterial Disease (CAD)
  • Inflammation
  • Heart Disease
  • Myocardial Infarct
  • Atherosclerotic Coronary Vascular Disease

Interventions

DRUG

Orticumab

Orticumab treatment for 24 weeks for post MI population

DRUG

Placebo

Placebo for 24 weeks for the post MI population

Sponsors & Collaborators

  • Abcentra

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-11
Primary Completion
2027-02-08
Completion
2027-06-01
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Hungary
  • Italy
  • Poland
  • Romania
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06927739 on ClinicalTrials.gov